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This paper demonstrates multiple benefits of intravitreal bevacizumab (IVB) on diabetic retinopathy (DR) including diabetic
macular edema (DME) and proliferative diabetic retinopathy (PDR) at 24 months of followup. This is a retrospective multicenter
interventional comparative case series of intravitreal injections of 1.25 or 2.5 mg of bevacizumab for DME, PDRwithout tractional
retinal detachment (TRD), and patients who experienced the development or progression of TRD after an intravitreal injection
of 1.25 or 2.5mg of bevacizumab before vitrectomy for the management of PDR. The results indicate that IVB injections may
have a beneficial eﬀect on macular thickness and visual acuity (VA) in diﬀuse DME. Therefore, in the future this new therapy
could complement focal/grid laser photocoagulation in DME. In PDR, this new option could be an adjuvant agent to panretina
photocoagulation so that more selective therapy may be applied. Finally, TRD in PDR may occur or progress after IVB used as
an adjuvant to vitrectomy. Surgery should be performed 4 days after IVB. Most patients had poorly controlled diabetes mellitus
associated with elevated HbA1c, insulin administration, PDR refractory to panretinal photocoagulation, and longer time between
IVB and vitrectomy.
1. Introduction
Diabetic retinopathy remains the major threat to sight in
the working age population in the developed world. Fur-
thermore, it is increasing as a major cause of blindness in
other parts of the world especially in developing countries
[1]. Diabetic macular edema (DME) is a manifestation of
diabetic retinopathy that produces loss of central vision.
Macular edema within 1 disk diameter of the fovea is
present in 9% of the diabetic population [2]. Although visual
loss secondary to proliferative changes is more common in
patients with type 1 diabetes, visual loss in patients with type
2 diabetes is more commonly due to macular edema [3].
Proliferative diabetic retinopathy (PDR) is a major cause of
visual loss in diabetic patients. In PDR, the growth of new
vessels from the retina or optic nerve, is thought to occur as
2 Journal of Ophthalmology
a result of vascular endothelial growth factor (VEGF) release
into the vitreous cavity as a response to ischemia [4–6].
Vascular endothelial growth factor has been shown to
be an endothelial cell-specific mitogen and an angiogenic
inducer in a variety of in vitro and in vivo models [7].
VEGF, also known as vascular permeability factor, has
been demonstrated to increase retinal vessel permeability by
increasing the phosphorylation of tight junction proteins.
Also, hypoxia has been shown to be amajor inducer of VEGF
gene transcription [7]. Recent work has found elevated
levels of VEGF in ocular fluids of patients with PDR
[4–6, 8]. Furthermore, injection of VEGF into normal
primate eyes induces the same pathological processes seen
in diabetic retinopathy, including microaneurysm formation
and increased vascular permeability [9, 10]. Because VEGF
has been shown to play a major role in macular edema and
retinal neovascularization (RN) [4, 5] although other factors
may be involved as well [9, 11] anti-VEGF treatments have
been hypothesized as an alternative adjunctive treatment for
DME [12, 13] and RN [14–16].
Bevacizumab (Avastin, Genentech Inc., San Francisco,
CA) is a complete full length humanized antibody that
binds to all subtypes of VEGF and is successfully used in
tumor therapy as a systemic drug [17]. Recent studies have
demonstrated the usefulness of an intravitreal injection of
bevacizumab in the reduction of macular edema secondary
to central retinal vein occlusion, vascular permeability,
and fibrovascular proliferation in RN secondary to PDR,
and choroidal neovascularization (CNV) secondary to age-
related macular degeneration (AMD) [13, 15, 16, 18–22].
The amount of human retinal penetration for a complete
full-length anti-VEGF antibody is not known at present.
However, full thickness retinal penetration of intravitreal
bevacizumab was observed in an animal model [23, 24].
Additionally, intravitreal bevacizumab does not appear to be
toxic to the albino rabbit retina at a concentration of up to
2.5mg [25].
In an open label uncontrolled clinical study of 4303 injec-
tions in human eyes with 1.25mg or 2.5mg IVT beva-
cizumab, our group [26] found systemic adverse events in 18
patients (1.5%). These included 7 (0.59%) cases of an acute
elevation of systemic blood pressure, 6 (0.5%), cerebrovas-
cular accident; 5 (0.4%), myocardial infarction; 2 (0.17%),
iliac artery aneurysms; and 2 (0.17%), toe amputations
as well as 5 (0.4%) deaths. Ocular complications included
7 (0.16%) cases of bacterial endophthalmitis, 7 (0.16%)
cases of tractional retinal detachment, 4 (0.09%) cases of
uveitis, and a case (0.02%) each of rhegmatogenous retinal
detachment and vitreous hemorrhage. Bevacizumab appears
to be safe and well tolerated during the first 12 months.
Recently, it has been reported that intravitreal injection
of bevacizumab may be also useful for early vitreous hem-
orrhage in PDR in order to decrease the risk of new hemor-
rhages while clearing occurs and to minimize the indications
of vitrectomy [15]. In addition, Chen and Park [27] and
Avery et al. [21] have suggested that preoperative intravitreal
bevacizumab might be helpful to facilitate vitrectomy in
severe PDR cases. In such cases, the preoperative use of beva-
cizumab might reduce the risk of intraoperative bleeding
facilitating the removal of fibrovascular membranes partic-
ularly when preoperative PRP cannot be placed. We have
previously reported 11 eyes (patients) out of 211 intravitreal
injections with development or progression of tractional
retinal detachment (TRD) with decrease best-corrected
visual acuity (BCVA) after intravitreal bevacizumab prior to
vitrectomy for the management of PDR for an incidence of
5.2% [28].
The purpose of this paper is to describe the anatomic
and functional outcomes, and the eﬀectiveness of intravitreal
bevacizumab (IVB) in patients with diabetic retinopathy at
24 months of followup.
2. Primary Intravitreal Bevacizumab (Avastin)
for Diffuse Diabetic Macular Edema
Diabetic macular edema is a manifestation of diabetic
retinopathy that produces loss of central vision. DME is
caused by excessive vascular permeability, resulting in the
leakage of fluid and plasma constituents, such as lipoproteins
into the retina, leading to thickening of the retina.
Although the Early Treatment Diabetic Retinopathy
Study (ETDRS) [29] demonstrated that immediate focal
photocoagulation reduced moderate visual loss by 50%
(from 24% to 12%, three years after initiation of treatment),
12% of treated eyes still lost 15 or more ETDRS letters at
the 3-year follow-up interval. Approximately 40% of treated
eyes that had retinal thickening involving the center of the
macula at baseline still had thickening involving the center
at 12 months, as did 25% of treated eyes at 36 months.
Furthermore, only 3% of laser-treated eyes experienced
a gain of 3 ormore lines of vision. This suggests that a distinct
subgroup of eyes exists with DME resistant to conventional
laser photocoagulation. Other studies have reported a poor
prognosis despite laser photocoagulation in eyes with diﬀuse
DME [29–31].
Given that most eyes with DME that are treated with
laser photocoagulation do not have an improvement in
visual acuity, there has been an interest in other treatment
modalities such as pharmacologic therapy with oral protein
kinase C inhibitors and the use of intravitreal corticosteroids
[32, 33]. The use of antibodies targeted at VEGF, is another
treatment modality that has generated considerable interest,
and is currently being investigated.
It was recently demonstrated that retinal hypoxia plays
a role in DME [34] and VEGF, which is upregulated by
hypoxia, is likely to contribute to the excessive vascular per-
meability that results in macular edema in people with dia-
betes. Several studies have demonstrated not only a correla-
tion of VEGF levels with the severity of diabetic retinopathy,
but also a reduction in levels after successful laser treatment
of PDR [9, 11]. Thus a rational approach to treating macular
edema in these patients would include the use of anti-
VEGF agents [14, 15]. Chun et al. reported that ranibizumab
(Lucentis, Genentech Inc., San Francisco, CA) therapy has
the potential to maintain or improve BCVA and reduce
retinal thickness in patients with DME [35]. In addition,
intravitreal injections of the aptamer pegaptanib sodium
(Macugen; OSI Eyetech Pharmaceuticals, Melville, NY)
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in patients with DME has been shown to improve visual
acuity (VA) and retinal thickening [12]. Cunningham and
coworkers reported gains in visual acuity of 10 letters in 34%
and 15 letters in 18% of patients with DME following an
intravitreal pegaptanib sodium injection in a randomized,
double-masked, multicenter trial with a followup of 36
months.
We have recently reported the 24-month anatomic and
BCVA response after primary intravitreal bevacizumab (IVB)
in patients with DME [13]. We conducted a multicenter ret-
rospective study of eyes with diﬀuse diabetic macular edema
(DDME) treated with oﬀ-label IVB between September 2005
and July 2006 at eleven institutions in Venezuela, Colombia,
Costa Rica, Brazil, Argentina, Spain, Peru, and Mexico. We
reviewed the clinical records of 115 consecutive patients
(139 eyes) with DDME treated with at least one intravitreal
injection of 1.25mg or 2.5mg of bevacizumab. The dose of
1.25mg or a dose of 2.5mg to be used to treat a patient
was determined at the discretion of the treating physician.
All patients with a minimum followup of 24 months.
Our patients had a mean age of 59.4 ± 11.1 years, and
51.3% were male. In that study, patients had a glycosylated
hemoglobin (HbA1c) mean of 9.1 ± 1.86%. Regarding the
severity of diabetic retinopathy (DR), 17 (12.2%) eyes had
mild DR, 25 (18%) eyes had moderate DR, 39 (28.1%)
eyes had severe DR, and 58 (41.7%) eyes had PDR. All
these 58 cases with PDR had had prior scatter panretinal
photocoagulation (PRP) at least 6 months before undergoing
IVB. All eyes had DDME diagnosed by biomicroscopic slit-
lamp examination, fluorescein angiography (FA), and optical
coherence tomography (OCT) (Stratus OCT, Carl Zeiss,
Dublin, CA) at baseline.
Exclusion criteria included patients (eyes) with DME
previously treated with laser photocoagulation or intravitreal
triamcinolone, macular ischemia, and the presence of an
epiretinal membrane or vitreomacular traction syndrome.
Patients received reinjections whenever there was a recur-
rence of DDME. Recurrence was defined as a decrease of
BCVA associated with an increase of intraretinal fluid due
to macular edema on OCT (≥50 µm in central macular
thickness) and/or FA, after complete or partial resolution in
previous followup visits.
Within one month after the initial bevacizumab injec-
tion, improvements in BCVA and central macular thickness
(CMT) measurements were observed and these significant
changes continued throughout the 24-month followup. At
one month BCVA improved from logMAR = 0.90 to 0.76,
a diﬀerence that was statistically significant (P < .001) (P =
.0001). This improvement in BCVAwasmaintained through-
out the 3-, 6-, 12-, and 24-month followup, (Figure 1).
In addition, the mean BCVA at 24 months was 20/100,
logMAR = 0.70 (P < .001) a statistically significant
diﬀerence from baseline BCVA. Twenty-four month BCVA
analysis by subgroups demonstrated that 62 (44.6%) eyes
remained stable, 72 (51.8%) eyes improved two or more
ETDRS lines of BCVA, and 5 (3.6%) eyes decreased two or
more ETDRS lines of BCVA.
Optical coherence tomography results were available for
all 139 eyes at 1-, 3-, 6-, 12-, and 24-month followups. At one
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Figure 1: Changes in best-corrected visual acuity (BCVA) after
intravitreal bevacizumab. BCVA improved at 1 month from 0.90 to
0.76 (logarithm of the minimum angle of resolution), a diﬀerence
that was statistically significant (P < .001), this level of BCVA was
maintained throughout 3-, 6-, 12-, and 24-months. CI: confidence
interval (Reprinted with permission from [13]).
month, the mean 1-mmCMTmeasurements decreased from
446.4µm ± 154.4µm to 333.75µm ± 117µm (P < .001),
and this overall improvement continued throughout the 24-
month followup, (Figures 2 and 3) . At 3-, 6-, 12-, and 24-
month follow-ups, mean CMT were 344.7µm ± 115.3µm,
321.7µm ± 102.7µm, 303µm ± 89.1µm, and 279.7 ± 80,
respectively, which were significantly diﬀerent from baseline
(P < .001).
In Figure 3(a) a horizontal OCT scan obtained through
the fovea revealed loss of the normal foveal contour, diﬀuse
macular thickening, areas of low intraretinal reflectivity
consistent with intraretinal cysts, and subretinal fluid (SRF).
The retinal map analysis revealed a foveal thickness of
619 µm. The patient underwent an intravitreal injection of
bevacizumab at a dose of 2.5mg in this eye. In Figure 3(b)
OCT reveals partial resolution of intraretinal macular edema
and complete reabsorption of SRF at one month after
bevacizumab injection. The retinal map analysis indicates
a central foveal thickness of 479 µm. Visual acuity (VA)
improved to 20/400. In Figure 3(c) 3 months after the
injection, the OCT scan shows improvement in foveal
thickness (306 µm). VA improved to 20/200. In Figure 3(d)
four months after the first injection, her VA diminished
to CF, and OCT scan showed the reappearance of macular
edema associated to the increase of intraretinal cysts. Central
foveal thickness increased to 715 µm. She received a second
injection of intravitreal bevacizumab at a dose of 2.5mg at
this point. In Figures 3(e) to 3(g), at month six she received a
third injection of intravitreal bevacizumab at dose de 2.5mg.
OCT scans at 5, 6, and 9 months showed a progressive
resolution in macular edema and intraretinal cysts, which
were confirmed with decrease of central foveal thickness
(400 µm, 318 µm, and 173 µm, resp.). VA also improves pro-
gressively (20/200, 20/200, and 20/125, resp.). In Figure 3(h)
twelve months after the first injection, the OCT scan showed
resolution of DME, with complete reabsorption of SRF and
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Figure 2: Changes in macular thickness with optical coherence
tomography (OCT) during followup after intravitreal bevacizumab.
The foveal thickness improved after 1 month, mean 1-mm central
macular thickness (CMT)measurement decreased from 446.4µm±
154.4µm to 333.75µm ± 117µm (P < .001), and this overall
improvement continued throughout the 24-month followup. At
3-, 6- 12- and 24-month followup were 344.7 ± 115.3µm, 321.7 ±
102.7µm, 303 ± 89.1µm and, 279.7 ± 80µm, respectively, which
were significantly lower than at 1-month followup (P < .001). CI:
confidence interval (Reprinted with permission from Arevalo JF,
Sanchez JG, Wu L, MaiaM, Alezzandrini AA, Brito M, Bonafonte S,
Lujan S, Diaz-Llopis M, Restrepo N, Rodrı´guez FJ, Udaondo-Mirete
P; Pan-American Collaborative Retina Study Group. Primary
intravitreal bevacizumab for diﬀuse diabetic macular edema the
Pan-American Collaborative Retina Study Group at 24 months.
Ophthalmology 2009; 116:1488-97, 1497.e1. Epub 2009 Jul 9).
restoration of foveal anatomy. Foveal thickness decreased
to 148 µm, and visual acuity was 20/125. In Figure 3(i)
sixteen months after the first injection, her VA diminished
to 20/400, and the OCT scan showed a reappearance of
macular edema associated to increased of intraretinal cysts.
Central foveal thickness increased to 557 µm. She received
a fourth injection of intravitreal bevacizumab at dose de
2.5mg. In Figure 3(j) OCT scan at 17 months showed a
resolution in macular edema and intraretinal cysts. Central
foveal thickness decreased to 245 µm and VA was 20/160. In
Figure 3(k) 18months after the first injection (2months after
the previous injection), the OCT scan shows improvement
in foveal thickness (200 µm). VA improved to 20/125. In
Figure 3(l) nineteen months after the first injection, his
visual acuity diminished to 20/400, and the OCT scan
showed the reappearance of macular edema. The retinal
map analysis indicates a central foveal thickness of 599 µm.
She received a fifth injection of intravitreal bevacizumab
at a dose of 2.5mg at this point. In Figure 3(m) OCT
scan at twenty months showed resolution in macular edema
and intraretinal cysts. Central foveal thickness decreased to
316 µm. VA improved to 20/200. In Figure 3(n) twenty-four
months after the first injection, OCT showed a marked
resolution in macular edema and restoration of foveal
anatomy. Central foveal thickness was 125 µm, and VA
improved to 20/160 (Reprinted with permission from [13]).
We wished to compare the response to treatment between
patients with PDR and previous PRP to those with nonpro-
liferative diabetic retinopathy and DDME to see if there was
any diﬀerence. However, when we ran the repeated measures
ANOVA to comparemean values to statistically analyze mean
retinal thickness and logMAR VA adjusting for the grade of
diabetic retinopathy as a covariate, we found no statistical
significance (P = .511 for BCVA and P = .483 for CMT).
All eyes received an intravitreal injection at the initial
visit; however, recurrences were retreated at the discretion
of the treating physician. There were a total of 807 IVB
injections performed. The mean number of IVB injections
per eye was 5.8 (range: 1 to 15 injections) at a mean interval
of 12.2±10.4 weeks. Seventy-four (53.2%) cases were treated
with an intravitreal injection of 1.25mg of bevacizumab and
sixty-five (46.8%) cases with at a dose of 2.5mg of IVB.
Adverse events included transient high blood pressure
in one (0.9%) patient, cerebrovascular accident in one
(0.9%) patient, heart attack in one (0.9%) patient, transient
increased intraocular pressure in seven (5%) eyes, cataract
in five (3.6%) eyes, and tractional retinal detachment in
one (0.7%) eye. There were no episodes of inflammation or
severe decrease of vision immediately after an injection.
Our results indicate that primary IVB at doses of 1.25mg
or 2.5mg seems to provide stability and improvement in
BCVA, OCT, and FA in DDME at 24 months. We identified
no diﬀerence in outcomes between IVB at doses of 1.25mg
or 2.5mg. Therefore, doses lower than 2.5mg should be
preferred. These results indicate that IVB injections may have
a beneficial eﬀect onmacular thickness and BCVA in DDME.
3. Intravitreal Bevacizumab (Avastin) for
Proliferative Diabetic Retinopathy
Panretinal photocoagulation (PRP) has been the mainstay
for the treatment of PDR, and its suppressive eﬀect on RN
has been well documented [36–39]. However, substantial
regression of new vessels may take weeks after completion
of PRP, and in up to one third of cases, new vessels continue
to grow despite initial PRP [37, 39]. In these cases, vitreous
hemorrhage may induce visual loss and prevent complete
laser. Moreover, macular edema may increase after PRP and
cause transient or persistent visual loss [40, 41].
Neovascularization on and around the optic disc (NVD)
and vitreous hemorrhage were found to be more frequently
associated with severe visual loss despite PRP in the Dia-
betic Retinopathy Study (DRS) and ETDRS [42, 43]. Long
intervals between PRP sessions and the variable amount
of time required for a favorable response may increase the
incidence of complications due to the progression of PDR
[36, 42]. In fact, a single episode of PRP or shorter intervals
between PRP episodes, although desirable in severe PDR and
when the patient must travel long distances for treatment,
are often associated with acute visual disturbances due to
exudative choroidal detachment, retinal detachment, and
macular edema [37, 44–46].
Although RN actually may be due to more than
one cytokine, VEGF is an important, if not the most
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Figure 3: Sequential optical coherence tomography (OCT) of a 69-year-old diabetic woman with a 6-months history of lost of vision to
counting fingers (CF) in her left eye that had developed diabetic macular edema (DME).
important cytokine involved [47]. Activation of the VEGF-
receptor pathway triggers a network of signaling processes
that promotes endothelial cell growth, migration, survival
from preexisting vessels, diﬀerentiation, and mobilization
of endothelial progenitor cells from the bone marrow
into the peripheral circulation [17, 48, 49]. Furthermore,
VEGF increases vessel permeability leading to deposition
of proteins in the interstitium that facilitate the process of
angiogenesis [50]. There are several reports published on the
intravitreal administration of anti-VEGF compounds for RN
in diabetic retinopathy [14, 21]. In addition, there are several
case reports on the use of intravitreal bevacizumab in RN in
diabetic retinopathy demonstrating regression of RN in PDR
[22, 27, 51–53].
We conducted a retrospective study in 43 eyes of 39
patients with PDR that had retinal neovascularization (RN),
who were treated with oﬀ-label intravitreal bevacizumab
between September 2005 and July 2007 at 7 institutions in
Venezuela, Costa Rica, Brazil, Argentina, Spain, and Peru.
Patients were followed for 24 months. Our patients had a
mean age of 54± 12.5 years old (range from 28 to 79 years),
and twenty-three (59%) patients were male. Eleven (28.2%)
diabetic patients were insulin dependent. The mean duration
of diabetes was 17.2 years (range from 1 to 33 years).
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Twenty-four (55.8%) eyes were treated with an intravitreal
injection of 1.25mg and 19 (44.2%) eyes were treated with
2.5mg of bevacizumab. Of the total of 43 eyes, 31 (72.1%)
eyes had been previously treated with scatter photocoag-
ulation at least 6 months before IVB, no eyes had prior
focal/grid laser photocoagulation, and no eyes had a previous
intravitreal triamcinolone injection. All eyes had clinical
significant macular edema (CSME) at biomicroscopic non-
contact fundus examination with a 66- or a 78-diopter lens.
The mean baseline BCVA was logMAR = 0.94 ±
0.38 ETDRS (20/176) and the mean 24-month BCVA was
logMAR = 0.67 ± 0.39 ETDRS (20/94) (P < .0005). Final
BCVA analysis by subgroups demonstrated that 35 (81.4%)
eyes remained stable, 5 (11.6%) eyes improved two or more
ETDRS lines of BCVA, and 3 (7%) eyes decreased two or
more ETDRS lines of BCVA.
Optical coherence tomography results were available for
all 43 eyes at 1-, 3-, 6-, 12-, and 24-month follow-up
time points. At 1 month, the mean 1-mm central macular
thickness (CMT) measurements decreased from 430.9µm±
169.5µm to 311.51µm ± 116µm (P < .05) (P = .01),
and this overall improvement continued throughout the 24-
month follow-up. At 3-, 6-, 12-, and 24-month follow-ups,
mean CMT were 319.6µm ± 95.7µm, 297.1µm± 102.5µm,
297.5µm±91.2µm and 270.3±75.9 respectively, which were
significantly diﬀerent from baseline (P = .0001).
Of the total of 43 eyes, 17 (39.5%) eyes treated showed
total regression of RN on fundus examination with absence
of fluorescein leakage, (Figure 4), 15 (34.9%) eyes demon-
strated partial regression of RN on fundus examination and
FA, and 11 (25.6) eyes showed no regression of RN (Table 1).
When divided by type of RN, of the total of 43 eyes,
15 (34.9%) eyes showed total regression of NVE (neovas-
cularization elsewhere) on fundus examination with absence
of fluorescein leakage, (Figure 4), 10 (23.3%) eyes demon-
strated partial regression of NVE on fundus examination
and FA, and twelve (27.9%) eyes showed no regression of
NVE. Thirteen (30.2%) eyes showed total regression of NVD
on fundus examination with absence of fluorescein leakage,
14 (32.5%) eyes demonstrated partial regression of NVD
on fundus examination and FA, and sixteen (37.2%) eyes
showed no regression of NVD.
When divided by IVB dose utilized, we observed that 9
(37.5%) eyes treated with 1.25mg dose showed no regression
of NVE and 13 (54.2%) eyes showed no regression of NVD at
the end of followup, while only 3 (15.8%) eyes treated with
2.5mg dose showed no regression of NVE, and 3 (15.8%)
eyes showed no regression of NVD at 24 months of followup.
These diﬀerences were statistically significant (P = .02) and
(P = .0001), respectively.
The mean number of IVB injections per eye was 4.1±2.1
(range: 1 to 8 injections) at a mean interval of 14.8±10.4wks.
Twenty-one eyes (47.7%) needed a second injection due to
recurrence of RN at a mean of 12.4 weeks (range from 4 to 34
weeks), and seven eyes (15.9%) needed a third injection due
to recurrence of neovascularization at a mean of 17.3 weeks
(range from 11 to 22 weeks).
Three patients without previous PRP (“naive”) and with
vitreous hemorrhage have avoided vitreoretinal surgery.
There were no episodes of inflammation or severe loss of
vision immediately after an injection. Regarding adverse
events at 24 months, two thromboembolic events were
reported, a cerebrovascular accident in 1 patient (2.6%) and
a myocardial infarction in 1 patient (2.6%). One TRD was
reported (2.3%), and one eye (2.3%) developed a vitreous
hemorrhage.
To determine the eﬀect of an intravitreal injection of
bevacizumab on actively growing new vessels, we chose
the variation in vitreous leakage from RN as our primary
outcome. The detection of NVD and NVE on FA allowed the
use of a systematic anatomical approach to monitor the area
of leaking new vessels over time. Finally, to determine the
eﬀect of an intravitreal injection of bevacizumab on macular
edema, we measured the variation on retinal thickness with
OCT.
Our studies have demonstrated that intravitreal beva-
cizumab resulted in marked regression of RN on fundus
examination and FA in patients with PDR and previous PRP,
specially in the first six months [16]. Furthermore, a rapid
resolution of vitreous hemorrhage in 3 naive eyes was seen.
In addition, IVB demonstrated a similar beneficial response
on macular thickness in eyes with PDR, and probably
bevacizumab prevents exacerbation of macular edema in
patients with concomitant CSME and PDR.
There was a tendency towards a decrease in response to
IVB overtime with 60.5% of eyes at 24 months requiring
additional PRP or vitrectomy, which raises the question of
tachyphylaxis. However, further analysis of our data seems to
rule out this possibility.
Intravitreal bevacizumab seems to be a useful treatment
for PDR, minimizing the risk for exudative complications,
progression of retinal neovascularization, vitreous hemor-
rhage, and decreased vision caused by macular edema.
Intravitreal bevacizumab may potentially be used as an adju-
vant agent to PRP for PDR.
4. Tractional Retinal Detachment following
Intravitreal Bevacizumab (Avastin)
in Patients with Severe Proliferative
Diabetic Retinopathy
In our updated retrospective review, we have identified 25
eyes (patients) out of 698 IVT injections that developed or
had progression of TRD with decrease of BCVA after intrav-
itreal bevacizumab prior to vitrectomy for the management
of PDR for an incidence of 3.5%.
All patients had had a PRP at least 2 months before
intravitreal bevacizumab. All eyes had PDR refractory to
PRP. The mean age of the study group was 61 ± 8.5
years (range from 24 to 76 years), and 52% were female.
Eighteen (72%) patients had DM type 2 with a mean of
14 ± 5.9 years from diagnosis (range: 1–25 years) and seven
(28%) patients had DM type 1 with a mean of 16.3 ± 8
years from diagnosis (range: 7 to 30 years). In the current
study, eleven (44%) patients used insulin administration as
sole treatment for glycemic control, seven (28%) diabetic
patients controlled glycemic levels with oral therapy, and the
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Table 1: Regression of RN on fundus examination with absence of fluorescein leakage after IVB at 24 months∗.
RN Regression
Unresponsive Neovascularization Naive Neovascularization
Total eyes
2.5mg 1.25mg 2.5mg 1.25mg
Total 5 7 2 3 17 (39.5%)
Partial 4 7 2 2 15 (34.9%)
No. 3 5 2 1 11 (25.6%)
Total eyes 12 19 6 6 43 (100%)
∗
RN: Retinal neovascularization, IVB: Intravitreal bavacizumab.
(a) (b)
Figure 4: A 53-year-old man had a 2-month history of visual loss to 20/60 in his right eye. We had performed panretinal photocoagulation
(PRP) in his right eye 2 years previously. Fundus examination revealed a mild vitreous hemorrhage. (a) Fluorescein leakage from neovascu-
larization of the disc (NVD) at baseline between retinal vessels crossing the optic disc was demonstrated. In addition, fluorescein angiography
(FA) showed magnification of retinal neovascularization elsewhere (NVE) in the superonasal retina. (b) At week 1 after intravitreal
bevacizumab, total resolution of leakage from NVD and NVE are shown. His visual acuity returned to 20/32 one month later. He needed
a reinjection at months 6, 14, and 24 of followup. A PRP was performed at 24 months.
remainder seven (28%) patients used combination therapy
with insulin and oral hypoglycemic agents for glycemic
control. However, all patients had uncontrolled diabetes
associated with elevated glycosylated hemoglobin (HbA1c
mean = 9.2%). Eleven (44%) eyes had local TRD on indirect
ophthalmoscopy, ultrasound, or biomicroscopic noncontact
fundus examination with a 66- or a 78-diopter lens before
intravitreal bevacizumab.
Twenty-five (3.2%) eyes (patients) out of 698 IVT
injections developed or had progression of TRD, (Figure 5).
Nineteen (73%) eyes had received a dose of 1.25mg (out of
626 injections: 3%), and 6 (27%) eyes had received a dose
of 2.5mg (out of 72 injections: 8.3%). Time from injection
to TRD had a mean of 11 ± 7.5 days (range from 5 to 32
days) and time from injection to vitrectomy had a mean of
18.8± 11.5 days (range from 5 to 37 days).
The mean baseline (before intravitreal bevacizumab)
BCVA was logMAR = 1.4 ± 0.7 (range from 0.2 to 2.9)
(mean ETDRS equivalent: 20/400; range: 20/32 to NLP).
At TRD development or progression, the mean BCVA was
logMAR = 1.9 ± 0.6 (range: 0.3 to 2.9) (mean ETDRS
equivalent: CF; range: 20/40 to NLP), this diﬀerence was
statistically significant compared to baseline BCVA (P ≤
.0001). One patient developed a retinal break as a result
of the increased traction, and a combined total tractional-
rhegmatogenous retinal detachment was apparent 3 weeks
after intravitreal bevacizumab.
Twenty-two eyes underwent vitrectomy, two patients
refused or were unable to undergo surgery, and in one
patient surgery was not recommended. Vitrectomy was
performed in a mean of 18.8± 11.5 days (range from 5 to 37
days) after intravitreal injection of bevacizumab. Tractional
retinal detachments were managed with vitrectomy, mem-
branectomy, photocoagulation, and extended intraocular
tamponade with gas in all patients that underwent surgery.
Final mean BCVA after surgery was logMAR = 1.4 (range:
0.2 to 2.9) (mean ETDRS equivalent: 20/400; range: 20/32 to
NLP), this diﬀerence was statistically significant compared
to TRD BCVA (P = .012). Subgroup analysis of final
BCVA after vitrectomy demonstrated that 12 (54.5%) out
of 22 eyes improved two or more ETDRS lines of BCVA
when compared to TRD BCVA. However, when compared
to baseline BCVA, final BCVA after vitrectomy demonstrated
that 8 (36.4%) eyes improved, 5 (22.7%) eyes remained
stable, and 9 (40.9%) eyes lost two or more ETDRS lines of
BCVA.
It could be argued that TRD may develop soon after
extensive PRP in diabetes. In addition, all our patients were
refractory to extensive PRP. However, all patients had had
a PRP at least 2 months before intravitreal bevacizumab.
The short time between the injection and TRD suggest
a cause-eﬀect relationship. It also suggests that in cases
at risk for progression of TRD that might involve the
central macular region, timely surgery should be anticipated
following intravitreal bevacizumab. All patients had TRDs
developed or progressed 5 days or more after the injection.
Therefore, surgery should be performed 4 days after IVB.
In addition, most of these patients had poorly controlled
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(g) (h) (i)
Figure 5: (a)–(c) Color photographs before intravitreal bevacizumab. Severe proliferative diabetic retinopathy with abundant fibrovascular
tissue and subhyaloid hemorrhage. The retina is attached and best-corrected visual acuity (BCVA) is 20/80. (d)–(f) Color photographs 10
days after 2.5mg of intravitreal bevacizumab demonstrating dense fibrous tissue contraction, and tractional retinal detachment withmacular
involvement. BCVA is hand motions at 2 meters. (g)–(i) Same eye, eight days after vitrectomy. The retina is reattached and best-corrected
visual acuity (BCVA) is 20/120 with silicone oil tamponade.
diabetes mellitus associated with elevated HbA1c, insulin
administration, PDR refractory to panretinal photocoagula-
tion, and longer time between intravitreal bevacizumab and
vitrectomy.
5. Risk Factors for the Development or
Progression of Tractional Retinal
Detachment following Intravitreal
Bevacizumab (Avastin) in Patients with
Severe ProliferativeDiabetic Retinopathy
Clinical parameters of patients previously identified as
potential risk factors for TRD were obtained and analyzed
and compared to the clinical characteristics of those patients
from the same cohort that did not develope a TRD after IVB
for PDR. We analyzed the presence or absence of 20 potential
risk factors for all patients with a TRD and compared them
to patients that did not develop a TRD. These potential
risk factors included systemic and surgical background,
age, time from diabetes mellitus (DM) diagnosis, glycemic
control, cholesterol levels, triglycerides levels, hemoglobin
A1c (HbA1C), dose of bevacizumab, and time from injection
to vitrectomy.
Twenty-Five eyes (patients) (3.5%) out of 698 intravitreal
injections developed or had progression to a TRD after
intravitreal bevacizumab. Patients with TDR were followed
for an average of 48.9 weeks (range: 0 to 190 weeks), and had
a mean age of 54.4 ± 11.5 years. Twelve were male (47.8%)
and thirteen were females (52.2%). Thirteen patients (52%)
were Hispanic, 6 (24%) were Caucasian, and 6 (24%) were
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African-American. Seventeen (68%) had diabetes type 2 and
8 (32%) had diabetes type 1. In the current study, twenty
(80%) patients with TRD had a previous PRP and had an
average HbA1c before treatment of 9.85 ± 2.6%. Seventeen
(68%) had less than 15 years diagnosed with DM and 8
(32%) had more than 15 years with a diagnosis of DM.
Patients without TRD were followed for an average of
33.1 weeks (range: 0 to 170 weeks) and had a mean age
of 53.94 ± 12.61 years. Four hundred and one were male
(59.6%) and 272 were female (40.4%). Four hundred and
fifty (66.9%) were Hispanic, 122 (18.1%) were Caucasian,
and 101 (15%) were African-American. One hundred ninety
patients (28.4%) had diabetes type 1 and 482 (71.6%) had
diabetes type 2. Four hundred seventy-two (70.15%) patients
without TRD had a previous PRP and had an average HbA1c
before treatment of 9.08 ± 2.11%. In addition, 242 (36.6%)
had less than 15 years of diagnosis with DM and 426 (63.3%)
had more than 15 years with a diagnosis of DM.
Of these 698 intravitreal injections, 626 applications were
with 1.25mg of bevacizumab (of which 19 patients had TRD,
3%) and 72 injections with 2.5mg of bevacizumab (of which
6 patients had TRD, 8.3%). No systemic adverse events such
as thromboembolic events (cerebrovascular accidents, tran-
sient ischemic attacks, myocardial infarctions, or peripheral
vascular disease) were reported. All eyes had TRD diagnosed
by indirect ophthalmoscopy, fundus biomicroscopy, FA, and
OCT at baseline.
Risk factors for TRD after IVB identified in our study
included, more than 15 years from the diagnosis of diabetes
mellitus (DM) (P = .009), (OR = 0.30), (95CI = 0.10–0.83),
(RR = 0.35), more than 13 days from injection to vitrectomy
(P = .0001), (OR = 9.9), (95CI = 3.4–29), (RR = 6.9) and
the use of a higher dose (2.5mg) of bevacizumab (P = .022),
(OR = 2.7), (95CI = 1.05–7.18), (RR = 2.38).
We did not find a statistical associations between others
risk factors and TRD, such as macular thickness (P = .123),
neovascular membrane (P = .145), or previous use of
bevacizumab (P = .653). Fibrovascular proliferation was
present in most patients with TRD (95%CI = 73.9–99.8).
However, no significant correlation was found between TRD
and fibrovascular proliferation despite that 94.7% of the
patients had this factor present (P = .260) (Table 2).
6. Conclusions
Diabetic macular edema is a manifestation of diabetic
retinopathy that produces loss of central vision, and is
the most frequent cause of visual impairment in patients
with nonproliferative diabetic retinopathy. However, the
breakdown of endothelial tight junctions and loss of the
blood retinal barrier that lead to DME can be associated
with both nonproliferative diabetic retinopathy and PDR.
Although several treatment modalities are currently under
investigation, the only demonstrated means to reduce the
risk of vision loss from DME are laser photocoagulation, as
demonstrated by the ETDRS, [29] intensive glycemic control,
as demonstrated by the Diabetes Control and Complications
Trial (DCCT) and the United Kingdom Prospective Diabetes
Study (UKPDS) and blood pressure control, as demonstrated
by the UKPDS [54, 55].
The results of our retrospective study demonstrated the
eﬃcacy of 1.25mg or 2.5mg of intravitreal bevacizumab
as primary treatment of DME as 51.8% of eyes showed
anatomical as well as functional improvement. In addition,
our results suggest a reduced risk of VA loss in eyes with
DME treated with intravitreal bevacizumab (97.1% of eyes).
All eyes received an intravitreal injection at the initial
visit; however, recurrences were retreated at the discretion
of the treating physician. There were a total of 807 IVB
injections performed. At 24 months, the mean number of
IVB injections per eye was 5.8 (range: 1 to 15 injections) at
a mean interval of 12.2 ± 10.4 weeks. Seventy-four (53.2%)
cases were treated with an intravitreal injection of 1.25mg
of bevacizumab and sixty-five (46.8%) cases with at a dose
of 2.5mg of IVB. The optimum dosing and sequence for
intravitreal bevacizumab in DME is still undetermined. We
elected to defer reinjections until there was a recurrence.
Our results indicate that intravitreal bevacizumab injec-
tions may have a beneficial eﬀect on macular thickness and
VA for DDME. Therefore, in the future this new treatment
modality could complement focal/grid laser photocoagula-
tion. Furthermore, focal/grid laser photocoagulation could
be used to consolidate the results obtained with one or a
series of intravitreal bevacizumab injections and decrease the
need for reinjections.
In addition, we demonstrated that intravitreal beva-
cizumab resulted in marked regression and then stability of
RN on fundus examination and FA in patients with PDR
and previous PRP. A rapid resolution of vitreous hemorrhage
can also be seen. Furthermore, intravitreal bevacizumab
demonstrated a similar beneficial response on macular
thickness in eyes with PDR, and probably bevacizumab
prevents exacerbation of macular edema in patients with
concomitant CSME and PDR. Regression of neovascular-
ization and decrease of retinal thickening occurred in some
injected eyes as soon as 7 to 15 days after the intravitreal
injection of bevacizumab. Twenty-one eyes (47.7%) needed
a second injection due to recurrence of neovascularization
at a mean of 12.4 weeks, and seven eyes (15.9%) needed
a third injection due to recurrence of neovascularization
at a mean of 17.3 weeks. We elected to defer reinjection
only when there was a recurrence of RN. Interestingly, we
noted that RN responded better to IVB at a dose of 2.5mg
than to a dose of 1.25mg. Nevertheless, the optimum dose
and dosing sequence for IVB is still undetermined. Another
interesting finding at 24 months is an increase in the number
of eyes that did not respond to IVB with complete RN
regression as compared to our previously published 6-month
data [16]. It is possible that over time the eﬀect of IVB on
RN diminishes, and that other means to control RN will
be necessary including PRP and vitrectomy. Although one
tractional retinal detachment was reported (1 eye; 2.3%)
and one (2.3%) eye developed a vitreous hemorrhage in our
series, further studies are needed to assess the eﬃcacy and
safety of IVB in the management of PDR.
We have identified 25 eyes (patients) out of 698 IVT
injections that developed or had progression of TRD with
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Table 2: Risk factors for tractional retinal detachment∗ .
Risk factor P CI 95%
More than 15 years from the diagnosis of diabetes mellitus .009‡ 0.10–0.83
More than 13 days from injection to vitrectomy .0001‡ 3.4–29
Use of a higher dose (2.5mg) of bevacizumab .022‡ 1.05–7.18
Diabetes Type .833 0.34–2.20
Fibrovascular proliferation .260 0.38–12.15
History of smoking .408 0.11–2.41
History of HTA .534 0.29–1.87
Prior Myocardial Infarction .10 0.088–2.73
Prior Cerebrovascular Accident .51 0.33–14.7
Total Cholesterol .895 0.16–4.53
Triglycerides .453 0.08–9.12
Hemoglobin levels .796 0.07–4.40
Macular Thickness of DME .123 0.33–11.65
Preretinal Hemorrhage .317 0.33–17.5
Vitreous Hemorrhage .292 0.24–1.47
Previous vitrectomy .632 0.49–24.97
∗
DME: Diabetic Macular Edema; TRD: Tractional Retinal Detachment; HTA: Hypertension.
‡Statistically significant.
decrease in BCVA after intravitreal bevacizumab prior to
vitrectomy for the management of PDR. The natural course
of PDR is characterized by a cycle of proliferation and
regression typical of new vessels; proliferation of fibrous
tissue accompanying new vessels; formation of adhesions
between the fibrovascular proliferations and the posterior
vitreous surface; contraction of the posterior vitreous surface
and associated proliferation. The development or progres-
sion of TRD in PDR following intravitreal bevacizumab
in our patients could have happened by natural history or
rapid neovascular involution with accelerated fibrosis and
posterior hyaloidal contraction as a response to decreased
levels of VEGF. In the current study, eleven (44%) patients
used insulin administration as sole therapy for glycemic
control, seven (28%) diabetic patients controlled glycemic
levels with oral therapy and the remainder seven (28%)
patients used combination therapy with insuline and oral
hypoglycemic agents for glycemic control. They all had
uncontrolled diabetes associated with elevated glycosylated
hemoglobin (HbA1c mean = 9.2%).
Results of this study suggest that TRD in PDR may
occur or progress after intravitreal bevacizumab used as
an adjuvant to vitrectomy. However, in the eyes that
underwent vitrectomy, we had the impression that there
was a reduced risk of intraoperative bleeding facilitating
the removal of fibrovascular membranes. A bloodless field
allows for better visibility and the surgeon may be less
likely to create an iatrogenic retinal break. In addition, the
chances of postoperative complications such as rebleeding or
fibrinoid syndrome may be decreased. All these advantages
may allow us to save more eyes utilizing preoperative
intravitreal bevacizumab regardless of increased traction
on some severe PDR cases. Moreover, most patients with
development or progression of TRD had poorly controlled
diabetes mellitus associated with elevated HbA1c, insulin
administration, PDR refractory to panretinal photocoagu-
lation, and longer time between intravitreal bevacizumab
and vitrectomy. These factors needed to be studied to
determine if they are indeed risk factors for the devel-
opment or progression of TRD after preoperative IVB in
PDR.
Finally, we did study the risk factors for the development
or progression of TRD after preoperative IVB in PDR. In
our retrospective review, we identified 25 eyes (patients)
with development or progression of TRD after intravitreal
bevacizumab prior to vitrectomy for the management of
PDR for an incidence of 3.5%; the risk factors associated with
these patients were more than 15 years from the diagnosis of
diabetes mellitus, more than 13 days from injection to vitrec-
tomy and the use of a higher dose (2.5mg) of bevacizumab.
Variables such as smoking history, hypertension, myocardial
infarction, levels of triglycerides, cholesterol, blood glucose,
previous vitreous hemorrhage, and macular thickness were
not related to the development or progression of tractional
retinal detachment.
Based on our data, we now believe that extreme caremust
be taken in using a dose of 2.5mg or more of bevacizumab
in patients with PDR. In addition, to have over 15 years
with a diagnosis of diabetes can increase the risk of TRD
and that careful follow-up evaluation following injection
is mandatory. The timing of surgery after the injection is
also important, as there are concerns that bevacizumab may
cause progression of the TRD. It is important that surgery
is performed once the antiangiogenic eﬀect of bevacizumab
has fully developed, but before there is further fibrous
proliferation; physicians must be prepared to perform the
vitrectomy preferably before 13 days after the application of
bevacizumab and to perform a vitrectomy immediately on
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those patients in whom a TRD occurs. The results of this
study show that intravitreal bevacizumab therapy is a well-
tolerated treatment option for PDR for carefully selected
patients, but we can safely assume that the application
of bevacizumab may lead to tractional retinal detachment
in a proportion of 3.58% (CI 95% = 2.13–5.03) of
patients.
7. Summary
Intravitreal bevacizumab seems to be a promising treatment
for PDR, minimizing the risk for exudative complications,
progression of retinal neovascularization, vitreous hemor-
rhage, and decreased vision caused by macular edema. In-
travitreal bevacizumab may potentially be used as an adju-
vant agent to PRP for PDR. In addition, primary intravitreal
bevacizumab at doses of 1.25mg or 2.5mg seems to provide
stability and improvement in VA, OCT, and FA in diabetic
macular edema. Evaluation in a multicenter, randomized,
controlled clinical trial with longer followup is needed
to evaluate the safety and eﬃcacy of this new treatment.
Tractional retinal detachment in PDR may occur or progress
after IVB used as an adjuvant to vitrectomy. Surgery should
be performed 4 days after IVB. Based on our multivariate
and bivariate analysis, risk factors for TRD after IVB in PDR
are time from diagnosis of DM of more than 15 years, time
interval from IVB to vitrectomy of more than 13 days, and
the use of the higher dose of IVB (2.5mg).
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